PFE - Why Is Moderna Stock Trading Lower On Wednesday? | Benzinga
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practice will meet this week to consider and recommend who should get respiratory syncytial virus (RSV), influenza, and COVID-19 vaccines.
In the presentation slides to the U.S. agency, Moderna Inc (NASDAQ:MRNA) shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up.
The data showed that vaccine efficacy fell to around 50% after 18 months on participants aged 60 years and above.
Vaccine efficacy in the infection with more than two symptoms was 50.3% and 49.9% in disease with three or more symptoms.
After a median of 3.7 months of follow-up, vaccine efficacy ...